Table 5. Ongoing Randomized Phase III Trials of Immunotherapy and Chemoradiotherapy in Locally-Advanced NSCLC.

	Eligible patients	Intervention	Estimated enrolment	Primary endpoint
CHECKMATE 73L NCT04026412	III	Arm A: Nivolumab + CRT → Nivolumab + Ipilimumab. Arm B: Nivolumab + CRT → Nivolumab. Arm C: Nivolumab + CRT → Durvalumab.	n=1400	DFS OS
PACIFIC 2 NCT03519971.	III	Arm A: Durvalumab + CRT → Durvalumab. Arm B: Placebo + CRT → Placebo.	n=328	DFS ORR
KEYNOTE 799 NCT03631784 * phase II trial	III	Cohort A: Pembrolizumab + Carboplatin + Paclitaxel × 1 cycles → Pembrolizumab × 2 cycles + weekly carbo/paclitaxel + RT → Pembrolizumab × 14 cycles. Cohort B: Pembrolizumab + Cisplatin + Pemetrexed × 3 cycles + RT → Pembrolizumab × 14 cycles.	n=210	Grade > 3 Pneumonitis ORR
EA5181 NCT04092283	III	Arm A: durvalumab + CRT → Durvalumab. Arm B: CRT → Durvalumab.	n=660	OS

CRT: Chemoradiotherapy, RT: Radiotherapy, pCR: Pathological complete response, MPR: Major pathological response, OS: Overall survival, DFS: Disease-free survival, ORR: Objective response rate